A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 45
Summary
- Conditions
- Breast Cancer
- Colorectal Carcinoma
- Melanoma
- Non Small Cell Lung Carcinoma
- Ovarian Cancer
- Pancreatic Carcinoma
- Prostate Cancer
- Renal Cell Carcinoma
- Solid Tumors
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02009449
- Collaborators
- ARMO BioSciences
- Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company